 SAN FRANCISCO and SUZHOU, China, Aug. 26, 2021 PRNewswire -- Innovent Biologics, Inc. Innovent HKEX: 01801, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Bolt Biotherapeutics, Inc. Bolt Nasdaq: BOLT, a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate ISAC candidates. The parties will leverage Innovents proprietary therapeutic antibody portfolio and discovery capability against undisclosed oncology targets in combination with Bolts advanced ISAC technology and myeloid biology expertise to create three new cancer treatments with the potential to provide significant benefit to patients. 